MedTrace Logo

A Study of Mapatumumab in Combination With Paclitaxel and Carboplatin in Subjects With Non-small Cell Lung Cancer

NCT00583830 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 111

Last updated 2013-08-08

No results posted yet for this study

Summary

The purpose of this study is to evaluate the efficacy (disease response) and safety of mapatumumab in combination with carboplatin and paclitaxel as first line therapy in subjects with advanced non-small cell lung cancer (NSCLC).

Conditions

  • Non Small Cell Lung Cancer

Interventions

BIOLOGICAL

Mapatumumab

30 mg/kg IV (in the vein), on day 1 of each 21 day cycle

BIOLOGICAL

Mapatumumab

10 mg/kg IV (in the vein), on day 1 of each 21 day cycle

DRUG

Paclitaxel

200 mg/m\^2 IV (in the vein), on day 1 of each 21 day cycle

DRUG

Carboplatin

AUC 6.0 mg min/ml IV (in the vein), on day 1 of each 21 day cycle

Sponsors & Collaborators

  • Human Genome Sciences Inc.

    lead INDUSTRY

Principal Investigators

  • GSK Clinical Trials · GlaxoSmithKline

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-01-31
Primary Completion
2010-11-30
Completion
2011-02-28

Countries

  • United States
  • Germany
  • Hungary
  • Romania

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00583830 on ClinicalTrials.gov